These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 23582356)

  • 1. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR.
    Moravsky G; Ofek E; Rakowski H; Butany J; Williams L; Ralph-Edwards A; Wintersperger BJ; Crean A
    JACC Cardiovasc Imaging; 2013 May; 6(5):587-96. PubMed ID: 23582356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy.
    Almaas VM; Haugaa KH; Strøm EH; Scott H; Smith HJ; Dahl CP; Geiran OR; Endresen K; Aakhus S; Amlie JP; Edvardsen T
    Heart; 2014 Apr; 100(8):631-8. PubMed ID: 24368281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis.
    Iles LM; Ellims AH; Llewellyn H; Hare JL; Kaye DM; McLean CA; Taylor AJ
    Eur Heart J Cardiovasc Imaging; 2015 Jan; 16(1):14-22. PubMed ID: 25354866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
    Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous contrast T1rho cardiac magnetic resonance for myocardial fibrosis in hypertrophic cardiomyopathy patients.
    Wang C; Zheng J; Sun J; Wang Y; Xia R; Yin Q; Chen W; Xu Z; Liao J; Zhang B; Gao F
    J Cardiol; 2015 Dec; 66(6):520-6. PubMed ID: 25981868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial Fibrosis in Hypertrophic Cardiomyopathy: Volumetric Assessment of Late Enhancement Provided by Cardiac Computed Tomography.
    Langer C; Schaefer P; Lutz M; Eden M; Hohnhorst M; Harders H; Faber L; Jansen O; Both M; Frey N
    J Comput Assist Tomogr; 2015; 39(5):797-803. PubMed ID: 26125299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
    Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
    J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Todiere G; Aquaro GD; Piaggi P; Formisano F; Barison A; Masci PG; Strata E; Bacigalupo L; Marzilli M; Pingitore A; Lombardi M
    J Am Coll Cardiol; 2012 Sep; 60(10):922-9. PubMed ID: 22935464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia.
    Kwon DH; Smedira NG; Rodriguez ER; Tan C; Setser R; Thamilarasan M; Lytle BW; Lever HM; Desai MY
    J Am Coll Cardiol; 2009 Jul; 54(3):242-9. PubMed ID: 19589437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy.
    Tezuka D; Kosuge H; Terashima M; Koyama N; Kishida T; Tada Y; Suzuki JI; Sasano T; Ashikaga T; Hirao K; Isobe M
    Heart Vessels; 2018 May; 33(5):513-520. PubMed ID: 29168014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragmented QRS on electrocardiography as a predictor of myocardial scar in patients with hypertrophic cardiomyopathy.
    Ratheendran AC; Subramanian M; Bhanu DK; Prabhu MA; Kannan R; Natarajan KU; Saritha Sekhar S; Thachathodiyil R; Harikrishnan MS; Pai PG
    Acta Cardiol; 2020 Feb; 75(1):42-46. PubMed ID: 30602338
    [No Abstract]   [Full Text] [Related]  

  • 16. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
    Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance.
    Flett AS; Hasleton J; Cook C; Hausenloy D; Quarta G; Ariti C; Muthurangu V; Moon JC
    JACC Cardiovasc Imaging; 2011 Feb; 4(2):150-6. PubMed ID: 21329899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.
    Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.